Loss of pleckstrin-2 reverts lethality and vascular occlusions in JAK2V617F-positive myeloproliferative neoplasms
Open Access
- 20 November 2017
- journal article
- research article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 128 (1) , 125-140
Abstract
V617F driver mutation of JAK2 is the leading cause of the Philadelphia-chromosome-negative myeloproliferative neoplasms (MPNs). Although thrombosis is a leading cause of mortality and morbidity in MPNs, the mechanisms underlying their pathogenesis are unclear. Here, we identified pleckstrin-2 (Plek2) as a downstream target of the JAK2/STAT5 pathway in erythroid and myeloid cells, and showed that it is upregulated in a JAK2V617F-positive MPN mouse model and in patients with MPNs. Loss of Plek2 ameliorated JAK2V617F-induced myeloproliferative phenotypes including erythrocytosis, neutrophilia, thrombocytosis, and splenomegaly, thereby reverting the widespread vascular occlusions and lethality in JAK2V617F-knockin mice. Additionally, we demonstrated that a reduction in red blood cell mass was the main contributing factor in the reversion of vascular occlusions. Thus, our study identifies Plek2 as an effector of the JAK2/STAT5 pathway and a key factor in the pathogenesis of JAK2V617F-induced MPNs, pointing to Plek2 as a viable target for the treatment of MPNs.Keywords
Funding Information
- NIDDK (DK102718)
- U.S. Department of War (CA140119)
- NHLBI (HL112792, HL120846, HL40387)
This publication has 51 references indexed in Scilit:
- Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosisLeukemia, 2013
- Comprehensive review of JAK inhibitors in myeloproliferative neoplasmsTherapeutic Advances in Hematology, 2012
- Formation of mammalian erythrocytes: chromatin condensation and enucleationTrends in Cell Biology, 2011
- Distinct Clinical Phenotypes Associated with JAK2V617F Reflect Differential STAT1 SignalingCancer Cell, 2010
- HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humansJournal of Clinical Investigation, 2010
- Transcriptional Profiling of Polycythemia Vera Identifies Gene Expression Patterns Both Dependent and Independent from the Action of JAK2V617FClinical Cancer Research, 2010
- Physiological Jak2V617F Expression Causes a Lethal Myeloproliferative Neoplasm with Differential Effects on Hematopoietic Stem and Progenitor CellsCancer Cell, 2010
- The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenesBlood, 2008
- PI3K regulates pleckstrin-2 in T-cell cytoskeletal reorganizationBlood, 2006
- A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia veraNature, 2005